US20130065786A1 - Method for breast cancer recurrence prediction under endocrine treatment - Google Patents

Method for breast cancer recurrence prediction under endocrine treatment Download PDF

Info

Publication number
US20130065786A1
US20130065786A1 US13/638,360 US201113638360A US2013065786A1 US 20130065786 A1 US20130065786 A1 US 20130065786A1 US 201113638360 A US201113638360 A US 201113638360A US 2013065786 A1 US2013065786 A1 US 2013065786A1
Authority
US
United States
Prior art keywords
genes
patient
combined score
il6st
ube2c
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/638,360
Other languages
English (en)
Inventor
Mareike Dartmann
Inke Sabine Feder
Mathias Gehrmann
Guido Hennig
Karsten Weber
Christian Von Törne
Ralf Kronenwett
Christoph Petry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad International GmbH
Original Assignee
Sividon Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sividon Diagnostics GmbH filed Critical Sividon Diagnostics GmbH
Assigned to SIVIDON DIAGNOSTICS GMBH reassignment SIVIDON DIAGNOSTICS GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HENNIG, GUIDO, KRONENWETT, RALF, PETRY, CHRISTOPH, WEBER, KARSTEN, GEHRMANN, MATHIAS, VON TOERNE, CHRISTIAN, FEDER, INKE SABINE, DARTMANN, MAREIKE
Publication of US20130065786A1 publication Critical patent/US20130065786A1/en
Assigned to MYRIAD INTERNATIONAL GMBH reassignment MYRIAD INTERNATIONAL GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SIVIDON DIAGNOSTICS GMBH
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer. More specific, the present invention relates to the prognosis of breast cancer based on measurements of the expression levels of marker genes in tumor samples of breast cancer patients.
  • breast cancer is one of the leading causes of cancer death in women in western countries. More specifically breast cancer claims the lives of approximately 40,000 women and is diagnosed in approximately 200,000 women annually in the United States alone. Over the last few decades, adjuvant systemic therapy has led to markedly improved survival in early breast cancer. This clinical experience has led to consensus recommendations offering adjuvant systemic therapy for the vast majority of breast cancer patients (EBCAG).
  • EBCAG adjuvant systemic therapy for the vast majority of breast cancer patients
  • endocrine treatment chemotherapy and treatment with targeted therapies.
  • Prerequisite for treatment with endocrine agents is expression of hormone receptors in the tumor tissue i.e. either estrogen receptor, progesterone receptor or both.
  • Tamoxifen has been the mainstay of endocrine treatment for the last three decades. Large clinical trials showed that tamoxifen significantly reduced the risk of tumor recurrence.
  • An additional treatment option is based on aromatase inhibitors which belong to a new endocrine drug class. In contrast to tamoxifen which is a competitive inhibitor of estrogen binding aromatase inhibitors block the production of estrogen itself thereby reducing the growth stimulus for estrogen receptor positive tumor cells. Still, some patients experience a relapse despite endocrine treatment and in particular these patients might benefit from additional therapeutic drugs.
  • Chemotherapy with anthracyclines, taxanes and other agents have been shown to be efficient in reducing disease recurrence in estrogen receptor positive as well as estrogen receptor negative patients.
  • the NSABP-20 study compared tamoxifen alone against tamoxifen plus chemotherapy in node negative estrogen receptor positive patients and showed that the combined treatment was more effective than tamoxifen alone.
  • the IBCSG IX study comparing tamoxifen alone against tamoxifen plus chemotherapy failed to show any significant benefit for the addition of cytotoxic agents.
  • a systemically administered antibody directed against the HER2/neu antigen on the surface of tumor cells have been shown to reduce the risk of recurrence several fold in a patients with Her2neu over expressing tumors.
  • Treatment guidelines are usually developed by renowned experts in the field. In Europe the St Gallen guidelines from the year 2009 recommend chemotherapy to patients with HER2 positive breast cancer as well as to patients with HER2 negative and ER negative disease. Uncertainty about the usefulness of chemotherapy arises in patients with HER2 negative and ER positive disease. In order to make a balanced treatment decision for the individual the likelihood of cancer recurrence is used as the most useful criteria. Clinical criteria like lymph node status, tumor grading, tumor size and others are helpful since they provide information about the risk of recurrence. More recently, multigene assays have been shown to provide information superior or additional to the standard clinical risk factors. It is generally recognized, that proliferation markers seem to provide the dominant prognostic information.
  • Prominent examples of those predictors are the Mammaprint test from Agendia, the Relapse Score from Veridex and the Genomic Grade Index, developed at the institute Jules Bordet and licensed to Ipsogen. All of these assays are based on determination of the expression levels of at least 70 genes and all have been developed for RNA not heavily degraded by formalin fixation and paraffin embedding, but isolated from fresh tissue (shipped in RNALaterTM). Another prominent multigene assay is the Recurrence Score test of Genomic Health Inc. The test determines the expression level of 16 cancer related genes and 5 reference genes after RNA extraction from formalin fixed and paraffin embedded tissue samples.
  • the current tools suffer from a lack of clinical validity and utility in the most important clinical risk group, i.e. those breast cancer patients of intermediate risk of recurrence based on standard clinical parameter. Therefore, better tools are needed to optimize treatment decisions based on patient prognosis.
  • a test with a high sensitivity and high negative predictive value is needed, in order not to undertreat a patient that eventually develops a distant metastasis after surgery.
  • the present invention fulfills the need for advanced methods for the prognosis of breast cancer on the basis of readily accessible clinical and experimental data.
  • cancer is not limited to any stage, grade, histomorphological feature, aggressivity, or malignancy of an affected tissue or cell aggregation.
  • predicting an outcome of a disease is meant to include both a prediction of an outcome of a patient undergoing a given therapy and a prognosis of a patient who is not treated.
  • the term “predicting an outcome” may, in particular, relate to the risk of a patient developing metastasis, local recurrence or death.
  • prediction relates to an individual assessment of the malignancy of a tumor, or to the expected survival rate (OAS, overall survival or DFS, disease free survival) of a patient, if the tumor is treated with a given therapy.
  • prognosis relates to an individual assessment of the malignancy of a tumor, or to the expected survival rate (OAS, overall survival or DFS, disease free survival) of a patient, if the tumor remains untreated.
  • An “outcome” within the meaning of the present invention is a defined condition attained in the course of the disease.
  • This disease outcome may e.g. be a clinical condition such as “recurrence of disease”, “development of metastasis”, “development of nodal metastasis”, development of distant metastasis”, “survival”, “death”, “tumor remission rate”, a disease stage or grade or the like.
  • a “risk” is understood to be a number related to the probability of a subject or a patient to develop or arrive at a certain disease outcome.
  • the term “risk” in the context of the present invention is not meant to carry any positive or negative connotation with regard to a patient's wellbeing but merely refers to a probability or likelihood of an occurrence or development of a given condition.
  • clinical data relates to the entirety of available data and information concerning the health status of a patient including, but not limited to, age, sex, weight, menopausal/hormonal status, etiopathology data, anamnesis data, data obtained by in vitro diagnostic methods such as histopathology, blood or urine tests, data obtained by imaging methods, such as x-ray, computed tomography, MRI, PET, spect, ultrasound, electrophysiological data, genetic analysis, gene expression analysis, biopsy evaluation, intraoperative findings.
  • imaging methods such as x-ray, computed tomography, MRI, PET, spect, ultrasound, electrophysiological data, genetic analysis, gene expression analysis, biopsy evaluation, intraoperative findings.
  • node positive means a patient having previously been diagnosed with lymph node metastasis. It shall encompass both draining lymph node, near lymph node, and distant lymph node metastasis. This previous diagnosis itself shall not form part of the inventive method. Rather it is a precondition for selecting patients whose samples may be used for one embodiment of the present invention. This previous diagnosis may have been arrived at by any suitable method known in the art, including, but not limited to lymph node removal and pathological analysis, biopsy analysis, in-vitro analysis of biomarkers indicative for metastasis, imaging methods (e.g. computed tomography, X-ray, magnetic resonance imaging, ultrasound), and intraoperative findings.
  • imaging methods e.g. computed tomography, X-ray, magnetic resonance imaging, ultrasound
  • biological sample is a sample which is derived from or has been in contact with a biological organism.
  • biological samples are: cells, tissue, body fluids, lavage fluid, smear samples, biopsy specimens, blood, urine, saliva, sputum, plasma, serum, cell culture supernatant, and others.
  • a “tumor sample” is a biological sample containing tumor cells, whether intact or degraded.
  • the sample may be of any biological tissue or fluid.
  • samples include, but are not limited to, sputum, blood, serum, plasma, blood cells (e.g., white cells), tissue, core or fine needle biopsy samples, cell-containing body fluids, urine, peritoneal fluid, and pleural fluid, liquor cerebrospinalis, tear fluid, or cells isolated therefrom. This may also include sections of tissues such as frozen or fixed sections taken for histological purposes or microdissected cells or extracellular parts thereof.
  • a tumor sample to be analyzed can be tissue material from a neoplastic lesion taken by aspiration or punctuation, excision or by any other surgical method leading to biopsy or resected cellular material.
  • tissue material from a neoplastic lesion taken by aspiration or punctuation, excision or by any other surgical method leading to biopsy or resected cellular material.
  • Such comprises tumor cells or tumor cell fragments obtained from the patient.
  • the cells may be found in a cell “smear” collected, for example, by a nipple aspiration, ductal lavage, fine needle biopsy or from provoked or spontaneous nipple discharge.
  • the sample is a body fluid.
  • Such fluids include, for example, blood fluids, serum, plasma, lymph, ascitic fluids, gynecologic fluids, or urine but not limited to these fluids.
  • a “gene” is a set of segments of nucleic acid that contains the information necessary to produce a functional RNA product.
  • a “gene product” is a biological molecule produced through transcription or expression of a gene, e.g. an mRNA, cDNA or the translated protein.
  • mRNA is the transcribed product of a gene and shall have the ordinary meaning understood by a person skilled in the art.
  • a “molecule derived from an mRNA” is a molecule which is chemically or enzymatically obtained from an mRNA template, such as cDNA.
  • expression level refers to a determined level of gene expression. This may be a determined level of gene expression as an absolute value or compared to a reference gene (e.g. a housekeeping gene), to the average of two or more reference genes, or to a computed average expression value (e.g. in DNA chip analysis) or to another informative gene without the use of a reference sample.
  • the expression level of a gene may be measured directly, e.g. by obtaining a signal wherein the signal strength is correlated to the amount of mRNA transcripts of that gene or it may be obtained indirectly at a protein level, e.g. by immunohistochemistry, CISH, ELISA or RIA methods.
  • the expression level may also be obtained by way of a competitive reaction to a reference sample.
  • An expression value which is determined by measuring some physical parameter in an assay, e.g. fluorescence emission may be assigned a numerical value which may be used for further processing of information.
  • a “reference pattern of expression levels”, within the meaning of the invention shall be understood as being any pattern of expression levels that can be used for the comparison to another pattern of expression levels.
  • a reference pattern of expression levels is, e.g., an average pattern of expression levels observed in a group of healthy individuals, diseased individuals, or diseased individuals having received a particular type of therapy, serving as a reference group, or individuals with good or bad outcome.
  • the term “mathematically combining expression levels”, within the meaning of the invention shall be understood as deriving a numeric value from a determined expression level of a gene and applying an algorithm to one or more of such numeric values to obtain a combined numerical value or combined score.
  • An “algorithm” is a process that performs some sequence of operations to produce information.
  • a “score” is a numeric value that was derived by mathematically combining expression levels using an algorithm. It may also be derived from expression levels and other information, e.g. clinical data. A score may be related to the outcome of a patient's disease.
  • a “discriminant function” is a function of a set of variables used to classify an object or event.
  • a discriminant function thus allows classification of a patient, sample or event into a category or a plurality of categories according to data or parameters available from said patient, sample or event.
  • Such classification is a standard instrument of statistical analysis well known to the skilled person.
  • a patient may be classified as “high risk” or “low risk”, “high probability of metastasis” or “low probability of metastasis”, “in need of treatment” or “not in need of treatment” according to data obtained from said patient, sample or event.
  • Classification is not limited to “high vs. low”, but may be performed into a plurality of categories, grading or the like.
  • Classification shall also be understood in a wider sense as a discriminating score, where e.g. a higher score represents a higher likelihood of distant metastasis, e.g. the (overall) risk of a distant metastasis.
  • discriminant functions which allow a classification include, but are not limited to functions defined by support vector machines (SVM), k-nearest neighbors (kNN), (naive) Bayes models, linear regression models or piecewise defined functions such as, for example, in subgroup discovery, in decision trees, in logical analysis of data (LAD) and the like.
  • SVM support vector machines
  • kNN k-nearest neighbors
  • LAD logical analysis of data
  • continuous score values of mathematical methods or algorithms such as correlation coefficients, projections, support vector machine scores, other similarity-based methods, combinations of these and the like are examples for illustrative purpose.
  • the term “therapy modality”, “therapy mode”, “regimen” as well as “therapy regimen” refers to a timely sequential or simultaneous administration of anti-tumor, and/or anti vascular, and/or immune stimulating, and/or blood cell proliferative agents, and/or radiation therapy, and/or hyperthermia, and/or hypothermia for cancer therapy.
  • the administration of these can be performed in an adjuvant and/or neoadjuvant mode.
  • the composition of such “protocol” may vary in the dose of the single agent, timeframe of application and frequency of administration within a defined therapy window.
  • cytotoxic chemotherapy refers to various treatment modalities affecting cell proliferation and/or survival.
  • the treatment may include administration of alkylating agents, antimetabolites, anthracyclines, plant alkaloids, topoisomerase inhibitors, and other antitumor agents, including monoclonal antibodies and kinase inhibitors.
  • the cytotoxic treatment may relate to a taxane treatment.
  • Taxanes are plant alkaloids which block cell division by preventing microtubule function.
  • the prototype taxane is the natural product paclitaxel, originally known as Taxol and first derived from the bark of the Pacific Yew tree.
  • Docetaxel is a semi-synthetic analogue of paclitaxel. Taxanes enhance stability of microtubules, preventing the separation of chromosomes during anaphase.
  • hormone treatment denotes a treatment which targets hormone signaling, e.g. hormone inhibition, hormone receptor inhibition, use of hormone receptor agonists or antagonists, use of scavenger- or orphan receptors, use of hormone derivatives and interference with hormone production.
  • hormone signaling e.g. hormone inhibition, hormone receptor inhibition, use of hormone receptor agonists or antagonists, use of scavenger- or orphan receptors, use of hormone derivatives and interference with hormone production.
  • hormone signaling e.g. hormone inhibition, hormone receptor inhibition, use of hormone receptor agonists or antagonists, use of scavenger- or orphan receptors, use of hormone derivatives and interference with hormone production.
  • hormone signaling e.g. hormone inhibition, hormone receptor inhibition, use of hormone receptor agonists or antagonists, use of scavenger- or orphan receptors, use of hormone derivatives and interference with hormone production.
  • tamoxifene therapy which modulates signaling of the estrogen receptor
  • aromatase treatment which interferes with ste
  • Tamoxifen is an orally active selective estrogen receptor modulator (SERM) that is used in the treatment of breast cancer and is currently the world's largest selling drug for that purpose. Tamoxifen is sold under the trade names Nolvadex, Istubal, and Valodex. However, the drug, even before its patent expiration, was and still is widely referred to by its generic name “tamoxifen.” Tamoxifen and Tamoxifen derivatives competitively bind to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that decreases RNA synthesis and inhibits estrogen effects.
  • SERM selective estrogen receptor modulator
  • Steroid receptors are intracellular receptors (typically cytoplasmic) that perform signal transduction for steroid hormones.
  • types include type I Receptors, in particular sex hormone receptors, e.g. androgen receptor, estrogen receptor, progesterone receptor; Glucocorticoid receptor, mineralocorticoid receptor; and type II Receptors, e.g. vitamin A receptor, vitamin D receptor, retinoid receptor, thyroid hormone receptor.
  • hybridization-based method refers to methods imparting a process of combining complementary, single-stranded nucleic acids or nucleotide analogues into a single double stranded molecule. Nucleotides or nucleotide analogues will bind to their complement under normal conditions, so two perfectly complementary strands will bind to each other readily. In bioanalytics, very often labeled, single stranded probes are used in order to find complementary target sequences. If such sequences exist in the sample, the probes will hybridize to said sequences which can then be detected due to the label. Other hybridization based methods comprise microarray and/or biochip methods.
  • probes are immobilized on a solid phase, which is then exposed to a sample. If complementary nucleic acids exist in the sample, these will hybridize to the probes and can thus be detected.
  • array based methods Yet another hybridization based method is PCR, which is described below. When it comes to the determination of expression levels, hybridization based methods may for example be used to determine the amount of mRNA for a given gene.
  • An oligonucleotide capable of specifically binding sequences a gene or fragments thereof relates to an oligonucleotide which specifically hybridizes to a gene or gene product, such as the gene's mRNA or cDNA or to a fragment thereof. To specifically detect the gene or gene product, it is not necessary to detect the entire gene sequence. A fragment of about 20-150 bases will contain enough sequence specific information to allow specific hybridization.
  • a PCR based method refers to methods comprising a polymerase chain reaction (PCR). This is a method of exponentially amplifying nucleic acids, e.g. DNA by enzymatic replication in vitro. As PCR is an in vitro technique, it can be performed without restrictions on the form of DNA, and it can be extensively modified to perform a wide array of genetic manipulations. When it comes to the determination of expression levels, a PCR based method may for example be used to detect the presence of a given mRNA by (1) reverse transcription of the complete mRNA pool (the so called transcriptome) into cDNA with help of a reverse transcriptase enzyme, and (2) detecting the presence of a given cDNA with help of respective primers. This approach is commonly known as reverse transcriptase PCR (rtPCR).
  • rtPCR reverse transcriptase PCR
  • PCR-based methods comprise e.g. real time PCR, and, particularly suited for the analysis of expression levels, kinetic or quantitative PCR (qPCR).
  • Quantitative PCR refers to any type of a PCR method which allows the quantification of the template in a sample.
  • Quantitative real-time PCR comprise different techniques of performance or product detection as for example the TaqMan technique or the LightCycler technique.
  • the TaqMan technique for examples, uses a dual-labelled fluorogenic probe.
  • the TaqMan real-time PCR measures accumulation of a product via the fluorophore during the exponential stages of the PCR, rather than at the end point as in conventional PCR.
  • the exponential increase of the product is used to determine the threshold cycle, CT, i.e.
  • the set up of the reaction is very similar to a conventional PCR, but is carried out in a real-time thermal cycler that allows measurement of fluorescent molecules in the PCR tubes.
  • a probe is added to the reaction, i.e., a single-stranded oligonucleotide complementary to a segment of 20-60 nucleotides within the DNA template and located between the two primers.
  • a fluorescent reporter or fluorophore e.g., 6-carboxyfluorescein, acronym: FAM, or tetrachlorofluorescin, acronym: TET
  • quencher e.g., tetramethylrhodamine, acronym: TAMRA, of dihydrocyclopyrroloindole tripeptide ‘black hole quencher’, acronym: BHQ
  • TAMRA tetramethylrhodamine
  • BHQ black hole quencher
  • array or “matrix” an arrangement of addressable locations or “addresses” on a device is meant.
  • the locations can be arranged in two dimensional arrays, three dimensional arrays, or other matrix formats.
  • the number of locations can range from several to at least hundreds of thousands. Most importantly, each location represents a totally independent reaction site.
  • Arrays include but are not limited to nucleic acid arrays, protein arrays and antibody arrays.
  • a “nucleic acid array” refers to an array containing nucleic acid probes, such as oligonucleotides, nucleotide analogues, polynucleotides, polymers of nucleotide analogues, morpholinos or larger portions of genes.
  • the nucleic acid and/or analogue on the array is preferably single stranded.
  • Arrays wherein the probes are oligonucleotides are referred to as “oligonucleotide arrays” or “oligonucleotide chips.”
  • a “microarray,” herein also refers to a “biochip” or “biological chip”, an array of regions having a density of discrete regions of at least about 100/cm2, and preferably at least about 1000/cm2.
  • Primer pairs and “probes”, within the meaning of the invention, shall have the ordinary meaning of this term which is well known to the person skilled in the art of molecular biology.
  • “primer pairs” and “probes”, shall be understood as being polynucleotide molecules having a sequence identical, complementary, homologous, or homologous to the complement of regions of a target polynucleotide which is to be detected or quantified.
  • nucleotide analogues are also comprised for usage as primers and/or probes.
  • Probe technologies used for kinetic or real time PCR applications could be e.g. TaqMan® systems obtainable at Applied Biosystems, extension probes such as Scorpion® Primers, Dual Hybridisation Probes, Amplifluor® obtainable at Chemicon International, Inc, or Minor Groove Binders.
  • “Individually labeled probes”, within the meaning of the invention, shall be understood as being molecular probes comprising a polynucleotide, oligonucleotide or nucleotide analogue and a label, helpful in the detection or quantification of the probe.
  • Preferred labels are fluorescent molecules, luminescent molecules, radioactive molecules, enzymatic molecules and/or quenching molecules.
  • arrayed probes within the meaning of the invention, shall be understood as being a collection of immobilized probes, preferably in an orderly arrangement.
  • the individual “arrayed probes” can be identified by their respective position on the solid support, e.g., on a “chip”.
  • substantially homologous refers to any probe that can hybridize (i.e., it is the complement of) the single-stranded nucleic acid sequence under conditions of low stringency as described above.
  • the present invention provides a method to assess the risk of recurrence of a node negative or positive, estrogen receptor positive and HER2/NEU negative breast cancer patient, in particular patients receiving endocrine therapy, for example when treated with tamoxifen.
  • Estrogen receptor status is generally determined using immunohistochemistry
  • HER2/NEU (ERBB2) status is generally determined using immunohistochemistry and fluorescence in situ hybridization.
  • estrogen receptor status and HER2/NEU (ERBB2) status may, for the purposes of the invention, be determined by any suitable method, e.g. immunohistochemistry, fluorescence in situ hybridization (FISH), or RNA expression analysis.
  • FISH fluorescence in situ hybridization
  • the present invention relates to a method for predicting an outcome of breast cancer in an estrogen receptor positive and HER2 negative tumor of a breast cancer patient, said method comprising:
  • BIRC5 may be replaced by UBE2C or TOP2A or RACGAP1 or AURKA or NEK2 or E2F8 or PCNA or CYBRD1 or DCN or ADRA2A or SQLE or CXCL12 or EPHX2 or ASPH or PRSS16 or EGFR or CCND1 or TRIM29 or DHCR7 or PIP or TFAP2B or WNT5A or APOD or PTPRT with the proviso that after a replacement 8 different genes are selected; and
  • UBE2C may be replaced by BIRC5 or RACGAP1 or TOP2A or AURKA or NEK2 or E2F8 or PCNA or CYBRD1 or ADRA2A or DCN or SQLE or CCND1 or ASPH or CXCL12 or PIP or PRSS16 or EGFR or DHCR7 or EPHX2 or TRIM29 with the proviso that after a replacement 8 different genes are selected; and
  • DHCR7 may be replaced by AURKA, BIRC5, UBE2C or by any other gene that may replace BIRC5 or UBE2C with the proviso that after a replacement 8 different genes are selected;
  • STC2 may be replaced by INPP4B or IL6ST or SEC14L2 or MAPT or CHPT1 or ABAT or SCUBE2 or ESR1 or RBBP8 or PGR or PTPRT or HSPA2 or PTGER3 with the proviso that after a replacement 8 different genes are selected; and
  • AZGP1 may be replaced by PIP or EPHX2 or PLAT or SEC14L2 or SCUBE2 or PGR with the proviso that after a replacement 8 different genes are selected;
  • RBBP8 may be replaced by CELSR2 or PGR or STC2 or ABAT or IL6ST with the proviso that after a replacement 8 different genes are selected;
  • IL6ST may be replaced by INPP4B or STC2 or MAPT or SCUBE2 or ABAT or PGR or SEC14L2 or ESR1 or GJA1 or MGP or EPHX2 or RBBP8 or PTPRT or PLAT with the proviso that after a replacement 8 different genes are selected; and
  • MGP may be replaced by APOD or IL6ST or EGFR with the proviso that after a replacement 8 different genes are selected.
  • Using the method of the invention before a patient receives endocrine therapy allows a prediction of the efficacy of endocrine therapy.
  • Table 2 shows whether the overexpression of each of the above marker genes is indicative of a good outcome or a bad outcome in a patient receiving endocrine therapy.
  • the skilled person can thus construct a mathematical combination i.e. an algorithm taking into account the effect of a given genes. For example a summation or weighted summation of genes whose overexpression is indicative of a good outcome results in an algorithm wherein a high risk score is indicative of a good outcome.
  • the validity of the algorithm may be examined by analyzing tumor samples of patients with a clinical record, wherein e.g. the score for good outcome patients and bad outcome patients may be determined separately and compared.
  • the skilled person, a biostatistician will know to apply further mathematical methods, such as discriminate functions to obtain optimized algorithms.
  • Algorithms may be optimized e.g. for sensitivity or specificity. Algorithms may be adapted to the particular analytical platform used to measure gene expression of marker genes, such as quantitiative PCR.
  • said endocrine therapy comprises tamoxifen or an aromatase inhibitor.
  • RNA expression level is determined as an RNA expression level.
  • the expression level of said at least on marker gene is determined as a pattern of expression relative to at least one reference gene or to a computed average expression value.
  • said step of mathematically combining comprises a step of applying an algorithm to values representative of an expression level of a given gene.
  • a method as described above wherein one, two or more thresholds are determined for said combined score and discriminated into high and low risk, high, intermediate and low risk, or more risk groups by applying the threshold on the combined score.
  • a high combined score is indicative of benefit from a more aggressive therapy, e.g. cytotoxic chemotherapy.
  • a “high score” in this regard relates to a reference value or cutoff value.
  • a “low” score below a cut off or reference value can be indicative of benefit from a more aggressive therapy, e.g. cytotoxic chemotherapy. This is the case when genes having a positive correlation with high risk of metastasis factor into the algorithm with a positive coefficient, such that an overall high score indicates high expression of genes having a positive correlation with high risk.
  • said information regarding nodal status is a numerical value ⁇ 0 if said nodal status is negative and said information is a numerical value>0 if said nodal status positive or unknown.
  • a negative nodal status is assigned the value 0
  • an unknown nodal status is assigned the value 0.5
  • a positive nodal status is assigned the value 1.
  • Other values may be chosen to reflect a different weighting of the nodal status within an algorithm.
  • the invention further relates to a kit for performing a method as described above, said kit comprising a set of oligonucleotides capable of specifically binding sequences or to seqences of fragments of the genes in a combination of genes, wherein
  • said combination comprises at least the 8 genes UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; or
  • said combination comprises at least the 10 genes BIRC5, AURKA, PVALB, NMU, STC2, RBBP8, PTGER3, CXCL12, CDH1, and PIP; or
  • said combination comprises at least the 9 genes BIRC5, DHCR7, RACGAP1, PVALB, STC2, IL6ST, PTGER3, CXCL12, and ABAT; or
  • said combination comprises at least the 9 genes DHCR7, RACGAP1, NMU, AZGP1, RBBP8, IL6ST, and MGP;
  • the invention further relates to the use of a kit for performing a method of any of claims 1 to 17 , said kit comprising a set of oligonucleotides capable of specifically binding sequences or to sequences of fragments of the genes in a combination of genes, wherein
  • said combination comprises at least the 8 genes UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; or
  • said combination comprises at least the 10 genes BIRC5, AURKA, PVALB, NMU, STC2, RBBP8, PTGER3, CXCL12, CDH1, and PIP; or
  • said combination comprises at least the 9 genes BIRC5, DHCR7, RACGAP1, PVALB, STC2, IL6ST, PTGER3, CXCL12, and ABAT; or
  • said combination comprises at least the 9 genes DHCR7, RACGAP1, NMU, AZGP1, RBBP8, IL6ST, and MGP;19.
  • a computer program product capable of processing values representative of an expression level of the genes AKR1C3, MAP4 and SPP1 by mathematically combining said values to yield a combined score, wherein said combined score is indicative of benefit from cytotoxic chemotherapy of said patient.
  • the invention further relates to a computer program product capable of processing values representative of an expression level of a combination of genes mathematically combining said values to yield a combined score, wherein said combined score is indicative of efficacy or benefit from endocrine therapy of said patient, according to the above methods.
  • Said computer program product may be stored on a data carrier or implemented on a diagnostic system capable of outputting values representative of an expression level of a given gene, such as a real time PCR system.
  • the computer program product is stored on a data carrier or running on a computer, operating personal can input the expression values obtained for the expression level of the respective genes.
  • the computer program product can then apply an algorithm to produce a combined score indicative of benefit from cytotoxic chemotherapy for a given patient.
  • the methods of the present invention have the advantage of providing a reliable prediction of an outcome of disease based on the use of only a small number of genes.
  • the methods of the present invention have been found to be especially suited for analyzing the response to endocrine treatment, e.g. by tamoxifen, of patients with tumors classified as ESR1 positive and ERBB2 negative.
  • FIG. 1 shows a Forrest Plot of the adjusted hazard unit ratio with 95% confidence intervall of the T5 score in the combined cohort, as well as the individual treatment arms of the ABCSG06 and 08 studies, using distant metastasis as endpoint.
  • FIG. 2 shows a Kaplan Meier Analysis of ER+, HER ⁇ , N0-3 patients from the combined ABCSG06 and 08 cohorts, stratified as high or low risk according to T5 Score value.
  • the method of the invention can be practiced using two technologies: 1.) Isolation of total RNA from fresh or fixed tumor tissue and 2.) Kinetic RT-PCR of the isolated nucleic acids.
  • RNA species might be isolated from any type of tumor sample, e.g. biopsy samples, smear samples, resected tumor material, fresh frozen tumor tissue or from paraffin embedded and formalin fixed tumor tissue.
  • RNA levels of genes coding for specific combinations of the genes UBE2C, BIRC5, DHCR7, RACGAP1, AURKA, PVALB, NMU, STC2, AZGP1, RBBP8, IL6ST, MGP, PTGER3, CXCL12, ABAT, CDH1, and PIP or specific combinations thereof, as indicated, are determined.
  • a prognostic score is calculated by a mathematical combination, e.g. according to formulas T5 T1, T4, or T5b (see below).
  • a high score value indicates a high risk for development of distant metastasis
  • a low score value indicates a low risk of distant metastasis. Consequently, a high score also indicates that the patient is a high risk patient who will benefit from a more aggressive therapy, e.g. cytotoxic chemotherapy.
  • the present examples are based on identification of prognostic genes using tumors of patients homogeneously treated in the adjuvant setting with tamoxifen. Furthermore, identification of relevant genes has been restricted to tumors classified as ESR1 positive and ERBB2 negative based on RNA expression levels. In addition, genes allowing separation of intermediate risk, e.g. grade 2 tumors were considered for algorithm development. Finally, a platform transfer from Affymetrix HG_U133a arrays to quantitative real time PCR, as well as a sample type transfer from fresh frozen tissue to FFPE tissue was performed to ensure robust algorithm performance, independent from platform and tissue type.
  • RNA was extracted with a Siemens, silica bead-based and fully automated isolation method for RNA from one 10 ⁇ m whole FFPE tissue section on a Hamilton MICROLAB STARlet liquid handling robot (17).
  • the robot, buffers and chemicals were part of a Siemens VERSANT® kPCR Molecular System (Siemens Healthcare Diagnostics, Tarrytown, N.Y.; not commercially available in the USA). Briefly, 150 ⁇ l FFPE buffer (Buffer FFPE, research reagent, Siemens Healthcare Diagnostics) were added to each section and incubated for 30 minutes at 80° C. with shaking to melt the paraffin. After cooling down, proteinase K was added and incubated for 30 minutes at 65° C.
  • tissue debris was removed from the lysis fluid by a 15 minutes incubation step at 65° C. with 40 ⁇ l silica-coated iron oxide beads.
  • the beads with surface-bound tissue debris were separated with a magnet and the lysates were transferred to a standard 2 ml deep well-plate (96 wells). There, the total RNA and DNA was bound to 40 ⁇ l unused beads and incubated at room temperature. Chaotropic conditions were produced by the addition of 600 ⁇ l lysis buffer. Then, the beads were magnetically separated and the supernatants were discarded. Afterwards, the surface-bound nucleic acids were washed three times followed by magnetization, aspiration and disposal of supernatants.
  • the nucleic acids were eluted by incubation of the beads with 100 ⁇ l elution buffer for 10 minutes at 70° C. with shaking. Finally, the beads were separated and the supernatant incubated with 12 ⁇ l DNase I Mix (2 ⁇ L DNase I (RNase free); 10 ⁇ l 10 ⁇ DNase I buffer; Ambion/Applied Biosystems, Darmstadt, Germany) to remove contaminating DNA. After incubation for 30 minutes at 37° C., the DNA-free total RNA solution was aliquoted and stored at ⁇ 80° C. or directly used for mRNA expression analysis by reverse transcription kinetic PCR (RTkPCR).
  • RTkPCR reverse transcription kinetic PCR
  • a platform transfer from Affymetrix HG_U133a arrays (fresh frozen tissue) to quantitative real time PCR (FFPE tissue) was calculated as follows. Material from 158 patients was measured using both platforms to yield paired samples. Delta-Ct values were calculated from the PCR data. Log 2-Expressions were calculated from the Affymetrix data by applying a lower bound (setting all values below the lower bound to the lower bound) and then calculating the logarithm of base 2. The application of a lower bound reduces the effect of increased relative measurement noise for low expressed genes/samples; a lower bound of 20 was used, lower bounds between 0.1 and 200 also work well.
  • a HG_U133a probe set was selected for each PCR-measured gene by maximizing the Pearson correlation coefficient between the delta-Ct value (from PCR) and the log 2-expression (from Affymetrix). Other correlation measures will also work well, e.g. the Spearman correlation coefficient. In most cases the best-correlating probe set belonged to the intended gene, for the remaining cases the PCR-gene was removed for further processing. Those genes showing a bad correlation between platforms were also removed, where a threshold on the Pearson correlation coefficient of 0.7 was used (values of between 0.5 and 0.8) also work well.
  • the platform transformation was finalized by calculating unsupervised z-transformations for both platforms and combining them; a single PCR-delta-Ct value then is transformed to the Affymetrix scale by the following steps: (i) apply affine linear transformation where coefficients were determined by z-transformation of PCR data, (ii) apply inverse affine linear transformation where coefficients were determined by z-transformation of Affymetrix data, (iii) invert log 2, i.e. calculate exponential with respect to base 2.
  • Alternatives to the two-fold z-transformations are linear or higher order regression, robust regression or principal component based methods, which will also work well.
  • Seq Seq gene probe ID forward primer ID ABAT TCGCCCTAAGAGGCTCTTCCTC 1 GGCAACTTGAGGTCTGACTTTTG 2 ADRA2A TTGTCCTTTCCCCCCTCCGTGC 4 CCCCAAGAGCTGTTAGGTATCAA 5 APOD CATCAGCTCTCAACTCCTGGTTTAACA 7 ACTCACTAATGGAAAACGGAAAGATC 8 ASPH TGGGAGGAAGGCAAGGTGCTCATC 10 TGTGCCAACGAGACCAAGAC 11 AURKA CCGTCAGCCTGTGCTAGGCAT 13 AATCTGGAGGCAAGGTTCGA 14 BIRC5 AGCCAGATGACGACCCCATAGAGGAACA 16 CCCAGTGTTTCTTCTGCTTCAAG 17 CELSR2 ACTGACTTTCCTTCTGGAGCAGGTGGC 19 TCCAAGCATGTATTCCAGACTTGT 20 CHPT1 CCACGGCCACCGAAGAGGCAC 22 CGCTCGTGCTCAT
  • Table 2 below, lists the genes used in the methods of the invention and in the particular embodiments T5, T1, T4, and T5b. Table 2 also shows whether overexpression of a given gene is indicative of good or bad outcome under Tamoxifen therapy. Table 2 lists the function of the gene, the compartment localization within the cell and the cellular processes it is involved in.
  • Table 3 shows the combinations of genes used for each algorithm.
  • Table 4 shows Affy probeset ID and TagMan design ID mapping of the marker genes of the present invention.
  • Table 5 shows full names, Entrez GeneID, gene bank accession number and chromosomal location of the marker genes of the present invention
  • T5 is a committee of four members where each member is a linear combination of two genes.
  • the mathematical formulas for T5 are shown below; the notation is the same as for T1.
  • T5 can be calculated from gene expression data only.
  • ⁇ ⁇ 177669 ⁇ [ - 0.267 ⁇ ⁇ ... ⁇ - 0.088 ] ⁇ * ⁇ ( 0.826 ⁇ * ⁇ STC ⁇ ⁇ 2 ⁇ - 3.630 )
  • ⁇ ⁇ risk riskMember ⁇ ⁇ 1 + riskMember ⁇ ⁇ 2 + riskMember ⁇ ⁇ 3 + riskMember ⁇ ⁇ 4
  • Coefficients on the left of each line were calculated as COX proportional hazards regression coefficients, the numbers in squared brackets denote 95% confidence bounds for these coefficients. In other words, instead of multiplying the term (0.939*BIRC5 ⁇ 3.831) with 0.434039, it may be multiplied with any coefficient between 0.301 and 0.567 and still give a predictive result with in the 95% confidence bounds.
  • Terms in round brackets on the right of each line denote a platform transfer from PCR to Affymetrix:
  • the variables PVALB, CDH1, . . . denote PCR-based expressions normalized by the reference genes (delta-Ct values), the whole term within round brackets corresponds to the logarithm (base 2) of Affymetrix microarray expression values of corresponding probe sets.
  • Kaplan Meier analysis was performed, after classifying the patients of the combined ABCSG cohorts using a predefined cut off for T5 score. Patients with a low risk of development of a distant metastasis had a T5 score ⁇ 9.3, while patients with a high risk of development of a distant metastasis had a T5 score above ⁇ 9.3. As shown in FIG. 2 , a highly significant separation of both risk groups is observed.
  • the T5 score was evaluated and compared against “Adjuvant! Online”, an online tool to aid in therapy selection based on entry of clinical parameters such as tumor size, tumor grade and nodal status.
  • Adjuvant!Online Relapse Risk score both scores remained a significant association with the development of distant metastasis.
  • Bivariate Cox regression using dichotomized data which were stratified according to T5 (cut off ⁇ 9.3) respectively to Adjuvant!Online (cut off 8), again yielded highly significant and independent associations with time to metastasis as clinical endpoint.
  • a high value of the T5 score indicates an increased risk of occurrence of distant metastasis in a given time period.
  • T1 is a committee of three members where each member is a linear combination of up to four variables.
  • variables may be gene expressions or clinical variables.
  • the only non-gene variable is the nodal status coded 0, if patient is lymph-node negative and 1, if patient is lymph-node-positive.
  • the mathematical formulas for T1 are shown below.
  • Coefficients on the left of each line were calculated as COX proportional hazards regression coefficients, the numbers in squared brackets denote 95% confidence bounds for these coefficients.
  • Terms in round brackets on the right of each line denote a platform transfer from PCR to Affymetrix:
  • the variables PVALB, CDH1, . . . denote PCR-based expressions normalized by the reference genes, the whole term within round brackets corresponds to the logarithm (base 2) of Affymetrix microarray expression values of corresponding probe sets.
  • Algorithm T4 is a linear combination of motifs.
  • the top 10 genes of several analyses of Affymetrix datasets and PCR data were clustered to motifs. Genes not belonging to a cluster were used as single gene-motifs. COX proportional hazards regression coefficients were found in a multivariate analysis.
  • motifs may be single gene expressions or mean gene expressions of correlated genes.
  • the mathematical formulas for T4 are shown below.
  • prolif ((0.84 [0.697 . . . 0.977]* RACGAP 1 ⁇ 2.174)+(0.85 [0.713 . . . 0.988]* DHCR 7 ⁇ 3.808)+(0.94 [0.786 . . . 1.089]* BIRC 5 ⁇ 3.734))/3
  • ptger 3 ( PTGER 3*0.57 [0.475 . . . 0.659]+1.436)
  • cxcl 12 ( CXCL 12*0.53 [0.446 . . . 0.618] ⁇ 0.847)
  • Factors and offsets for each gene denote a platform transfer from PCR to Affymetrix:
  • the variables RACGAP1, DHCR7, . . . denote PCR-based expressions normalized by CALM2 and PPIA, the whole term within round brackets corresponds to the logarithm (base 2) of Affymetrix microarray expression values of corresponding probe sets.
  • Coefficients of the risk were calculated as COX proportional hazards regression coefficients, the numbers in squared brackets denote 95% confidence bounds for these coefficients.
  • T5b is a committee of two members where each member is a linear combination of four genes.
  • the mathematical formulas for T5b are shown below, the notation is the same as for T1 and T5.
  • a non-gene variable is the nodal status coded 0, if patient is lymph-node negative and 1, if patient is lymph-node-positive and 0.5 if the lymph-node status is unknown.
  • T5b is defined by:
  • Example algorithm T5 is a committee predictor consisting of 4 members with 2 genes of interest each. Each member is an independent and self-contained predictor of distant recurrence, each additional member contributes to robustness and predictive power of the algorithm to predict time to metastasis, time to death or likelihood of survival for a breast cancer patient.
  • the equation below shows the “Example Algorithm T5”; for ease of reading the number of digits after the decimal point has been truncated to 2; the range in square brackets lists the estimated range of the coefficients (mean+/ ⁇ 3 standard deviations).
  • Gene names in the algorithm denote the difference of the mRNA expression of the gene compared to one or more housekeeping genes as described above.
  • the performance of the one member committees as shown in an independent cohort of 234 samples is notably reduced compared to the performance of the full algorithm. Still, using a committee consisting of fewer members allows for a simpler, less costly estimate of the risk of breast cancer recurrence or breast cancer death that might be acceptable for certain diagnostic purposes.
  • Described algorithms such as “Example algorithm T5”, above can be also be modified by replacing one or more genes by one or more other genes.
  • the purpose of such modifications is to replace genes difficult to measure on a specific platform by a gene more straightforward to assay on this platform. While such transfer may not necessarily yield an improved performance compared to a starting algorithm, it can yield the clue to implanting the prognostic algorithm to a particular diagnostic platform.
  • replacing one gene by another gene while preserving the diagnostic power of the predictive algorithm can be best accomplished by replacing one gene by a co-expressed gene with a high correlation (shown e.g. by the Pearson correlation coefficient).
  • T5 consists of four independent committee members one has to re-train only the member that contains the replaced gene.
  • the following equations demonstrate replacements of genes of the T5 algorithm shown above trained in a cohort of 234 breast cancer patients. Only one member is shown below, for c-index calculation the remaining members were used unchanged from the original T5 Algorithm.
  • the range in square brackets lists the estimated range of the coefficients: mean+/ ⁇ 3 standard deviations.
  • the following table shows potential replacement gene candidates for the genes of T5 algorithm. Each gene candidate is shown in one table cell: The gene name is followed by the bracketed absolute Pearson correlation coefficient of the expression of the original gene in the T5 Algorithm and the replacement candidate, and the HG-U133A probe set ID.
  • a second alternative for unsupervised selection of possible gene replacement candidates is based on Affymetrix data only. This has the advantage that it can be done solely based on already published data (e.g. from www.ncbi.nlm.nih.gov/geo/).
  • the following table (Tab. 10) lists HG-U133a probe set replacement candidates for the probe sets used in algorithms T1-T5. This is based on training data of these algorithms.
  • the column header contains the gene name and the probe set ID in bold.
  • the 10 best-correlated probe sets are listed, where each table cell contains the probe set ID, the correlation coefficient in brackets and the gene name.
  • the Pearson correlation coefficient is 0.73.
  • the regression method assumes measurement noise on BIRC5, but no noise on RACGAP1. Therefore the mapping is not symmetric with respect to exchangeability of the two variables.
  • a symmetric mapping approach would be based on two univariate z-transformations.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US13/638,360 2010-03-31 2011-03-29 Method for breast cancer recurrence prediction under endocrine treatment Abandoned US20130065786A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10158561.0 2010-03-31
EP10158561 2010-03-31
PCT/EP2011/054855 WO2011120984A1 (en) 2010-03-31 2011-03-29 Method for breast cancer recurrence prediction under endocrine treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/054855 A-371-Of-International WO2011120984A1 (en) 2010-03-31 2011-03-29 Method for breast cancer recurrence prediction under endocrine treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/234,828 Continuation US10577661B2 (en) 2010-03-31 2016-08-11 Method for breast cancer recurrence prediction under endocrine treatment

Publications (1)

Publication Number Publication Date
US20130065786A1 true US20130065786A1 (en) 2013-03-14

Family

ID=43857901

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/638,360 Abandoned US20130065786A1 (en) 2010-03-31 2011-03-29 Method for breast cancer recurrence prediction under endocrine treatment
US15/234,828 Active 2032-05-29 US10577661B2 (en) 2010-03-31 2016-08-11 Method for breast cancer recurrence prediction under endocrine treatment
US16/746,334 Active US10851427B2 (en) 2010-03-31 2020-01-17 Method for breast cancer recurrence prediction under endocrine treatment
US17/081,924 Active 2032-08-06 US11913078B2 (en) 2010-03-31 2020-10-27 Method for breast cancer recurrence prediction under endocrine treatment
US18/410,966 Pending US20240229150A1 (en) 2010-03-31 2024-01-11 Method for breast cancer recurrence prediction under endocrine treatment

Family Applications After (4)

Application Number Title Priority Date Filing Date
US15/234,828 Active 2032-05-29 US10577661B2 (en) 2010-03-31 2016-08-11 Method for breast cancer recurrence prediction under endocrine treatment
US16/746,334 Active US10851427B2 (en) 2010-03-31 2020-01-17 Method for breast cancer recurrence prediction under endocrine treatment
US17/081,924 Active 2032-08-06 US11913078B2 (en) 2010-03-31 2020-10-27 Method for breast cancer recurrence prediction under endocrine treatment
US18/410,966 Pending US20240229150A1 (en) 2010-03-31 2024-01-11 Method for breast cancer recurrence prediction under endocrine treatment

Country Status (17)

Country Link
US (5) US20130065786A1 (es)
EP (2) EP2845911B1 (es)
JP (2) JP5940517B2 (es)
KR (1) KR101864855B1 (es)
CN (2) CN102971435B (es)
BR (2) BR122020016370B1 (es)
CA (1) CA2793133C (es)
ES (2) ES2525382T3 (es)
HK (1) HK1181817A1 (es)
HU (1) HUE030164T2 (es)
MX (1) MX2012011167A (es)
PL (2) PL2845911T3 (es)
PT (2) PT2845911T (es)
RU (1) RU2654587C2 (es)
UA (1) UA110790C2 (es)
WO (1) WO2011120984A1 (es)
ZA (1) ZA201207229B (es)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038682A1 (en) * 2013-09-11 2015-03-19 bio Theranostics, Inc. Predicting breast cancer recurrence
WO2015042570A1 (en) * 2013-09-23 2015-03-26 The University Of Chicago Methods and compositions relating to cancer therapy with dna damaging agents
WO2019051266A3 (en) * 2017-09-08 2019-06-20 Myriad Genetics, Inc. Method of using biomarkers and clinical variables for predicting chemotherapy benefit
US10329624B2 (en) 2001-12-21 2019-06-25 Biotheranostics, Inc. Grading of breast cancer
CN110050075A (zh) * 2016-10-27 2019-07-23 通用医疗公司 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析
US10851427B2 (en) 2010-03-31 2020-12-01 Myriad International Gmbh Method for breast cancer recurrence prediction under endocrine treatment
US11459617B2 (en) * 2016-04-29 2022-10-04 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
US11898209B2 (en) 2015-03-25 2024-02-13 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2737081B1 (en) 2011-07-28 2016-09-28 Sividon Diagnostics GmbH Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer
MX357402B (es) * 2011-11-08 2018-07-09 Genomic Health Inc Metodo para predecir el pronostico de cancer de mama.
EP2852689B1 (en) * 2012-05-22 2019-12-11 Nanostring Technologies, Inc. Nano46 genes and methods to predict breast cancer outcome
WO2013188600A1 (en) * 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
WO2013190081A1 (en) * 2012-06-22 2013-12-27 Proyecto De Biomedicina Cima, S.L. Methods and reagents for the prognosis of cancer
DK2951317T3 (en) 2013-02-01 2018-01-15 Sividon Diagnostics Gmbh PROCEDURE FOR PREDICTING THE BENEFIT OF INCLUSING TAXAN IN A CHEMOTHERAPY PLAN FOR BREAST CANCER PATIENTS
WO2014181782A1 (ja) * 2013-05-07 2014-11-13 独立行政法人国立がん研究センター 胃がんの再発を予測する方法
EP2997163A4 (en) * 2013-05-13 2017-02-22 Nanostring Technologies, Inc Methods to predict risk of recurrence in node-positive early breast cancer
US20160186270A1 (en) * 2013-08-02 2016-06-30 Université Catholique de Louvain Signature of cycling hypoxia and use thereof for the prognosis of cancer
KR101548830B1 (ko) * 2013-12-30 2015-08-31 가천대학교 산학협력단 줄기세포 배양방법을 이용하여 발굴된 유방암 줄기세포 마커를 이용한 유방암 예후 예측용 조성물
WO2015110440A1 (en) * 2014-01-22 2015-07-30 Koninklijke Philips N.V. Improved stratification of patients for assessing the suitability of a therapy
RU2566732C1 (ru) * 2014-07-08 2015-10-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ онкологии" СО РАМН) Способ прогнозирования лимфогенного метастазирования при инвазивной карциноме неспецифического типа молочной железы
CN104263815B (zh) * 2014-08-25 2017-01-25 复旦大学附属肿瘤医院 一组用于激素受体阳性乳腺癌预后的基因及其应用
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
WO2017153546A1 (en) 2016-03-09 2017-09-14 Sividon Diagnosticg Gmbh Method for determining the risk of recurrence of an estrogen receptor-positive and her2-negative primary mammary carcinoma under an endocrine therapy
EP3442566A4 (en) * 2016-04-14 2019-11-20 Academia Sinica INHIBITION OF SCUBE2, A NOVEL VEGFR2 CO RECEPTOR, FOR SUPPRESSING THE TUMORANGIOGENESIS
CN106480201A (zh) * 2016-10-26 2017-03-08 北京鑫诺美迪基因检测技术有限公司 乳腺癌转移评估试剂盒
KR101950717B1 (ko) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 유방암 환자의 화학치료 유용성 예측 방법
KR101896545B1 (ko) * 2016-11-25 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
RU2671557C1 (ru) * 2017-07-10 2018-11-02 Александр Григорьевич Тоневицкий Набор реагентов для определения риска возникновения рецидива онкологических заболеваний молочной железы
CN108441559B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种免疫相关基因群作为标志物在制备评估高增殖性乳腺癌远处转移风险的产品中的应用
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
CN108715804A (zh) * 2018-05-14 2018-10-30 浙江大学 一种群智能寻优的肺癌癌细胞检测仪
CN108424969B (zh) * 2018-06-06 2022-07-15 深圳市颐康生物科技有限公司 一种生物标志物、诊断或预估死亡风险的方法
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
US20220042999A1 (en) * 2018-12-06 2022-02-10 Georgia State University Research Foundation, Inc. Quantitative Centrosomal Amplification Score to Predict Local Recurrence of Ductal Carcinoma In Situ
JP2022540090A (ja) * 2019-07-05 2022-09-14 インテレクソン・ゲーエムベーハー 個人のｈｌａパターンの決定、予後因子としての使用、標的遺伝子、及び治療薬
WO2021055517A1 (en) * 2019-09-16 2021-03-25 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatments based upon molecular characterization of breast cancer
KR102325945B1 (ko) * 2020-04-22 2021-11-12 아주대학교산학협력단 두경부암 예후 예측용 바이오마커 조성물
CN112852968A (zh) * 2021-04-08 2021-05-28 杨文琳 基于免疫相关lncRNA构建三阴性乳腺癌风险预测方法
CN114480652A (zh) * 2022-02-21 2022-05-13 深圳市陆为生物技术有限公司 评价乳腺癌患者对于辅助内分泌治疗的响应性的产品

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070134688A1 (en) * 2005-09-09 2007-06-14 The Board Of Regents Of The University Of Texas System Calculated index of genomic expression of estrogen receptor (er) and er-related genes
US20100105564A1 (en) * 2006-09-15 2010-04-29 Mcgill University Stroma Derived Predictor of Breast Cancer
US20110145176A1 (en) * 2008-05-30 2011-06-16 Perou Charles M Gene expression profiles to predict breast cancer outcomes

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
JP4277452B2 (ja) 2000-02-25 2009-06-10 ソニー株式会社 記録装置、再生装置
EA006512B1 (ru) * 2001-04-27 2005-12-29 Институт молекулярной биологии им. В.А.Энгельгардта РАН Способы анализа последовательностей нуклеиновых кислот с использованием биологического олигонуклеотидного микрочипа и наборы для их осуществления
WO2003001985A2 (en) 2001-06-28 2003-01-09 Dermtech International Method for detection of melanoma
US20040002067A1 (en) 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
FR2863275B1 (fr) * 2003-12-09 2007-08-10 Biomerieux Sa Procede pour le diagnostic/pronostic du cancer du sein
EP1721159B1 (en) * 2004-02-20 2014-12-10 Janssen Diagnostics, LLC Breast cancer prognostics
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
CA2585561C (en) 2004-11-05 2018-07-17 Genomic Health, Inc. Esr1, pgr, bcl2 and scube2 group score as indicators of breast cancer prognosis and prediction of treatment response
JP2008536094A (ja) 2005-02-04 2008-09-04 ロゼッタ インファーマティクス エルエルシー 乳癌患者における化学療法反応性を予測する方法
CN101356532B (zh) * 2005-05-13 2012-08-01 布鲁塞尔自由大学 基于基因的算法型癌症预后
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
GB0512299D0 (en) 2005-06-16 2005-07-27 Bayer Healthcare Ag Diagnosis prognosis and prediction of recurrence of breast cancer
US20090239223A1 (en) * 2006-07-13 2009-09-24 Siemens Healthcare Diagnostics Inc. Prediction of Breast Cancer Response to Taxane-Based Chemotherapy
CA2671461C (en) 2006-12-01 2014-01-28 The Regents Of The University Of California Vesicles of self-assembling block copolymers and methods for making and using the same
RU2473555C2 (ru) * 2006-12-19 2013-01-27 ДжинГоу, Инк. Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
EP2036988A1 (en) 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2009095319A1 (en) 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
WO2010003773A1 (en) * 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
EP2469440A3 (en) 2008-06-16 2014-01-01 Sividon Diagnostics GmbH Molecular markers for cancer prognosis
EP2163649A1 (en) * 2008-09-11 2010-03-17 Fédération Nationale des Centres de Lutte Contre le Cancer Molecular classifier for evaluating the risk of metastasic relapse in breast cancer
KR101192297B1 (ko) 2008-12-10 2012-10-17 한국생명공학연구원 간암에 대한 신규 바이오마커 및 그의 용도
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
EP2419532A1 (en) 2009-04-17 2012-02-22 Université Libre de Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
US8546091B2 (en) 2009-05-22 2013-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AKT phosphorylation at Ser473 as an indicator for taxane-based chemotherapy
WO2011121028A1 (en) 2010-03-30 2011-10-06 Siemens Healthcare Diagnostics Inc. Algorithm for prediction of benefit from addition of taxane to standard chemotherapy in patients with breast cancer
KR101864855B1 (ko) 2010-03-31 2018-07-13 지피돈 디아그노스틱스 게엠베하 내분비 치료 중 유방암 재발 예측 방법
WO2012153187A2 (en) 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
EP2737081B1 (en) 2011-07-28 2016-09-28 Sividon Diagnostics GmbH Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer
CA2857191A1 (en) 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
WO2013188600A1 (en) 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
EP3105344A1 (en) 2014-02-12 2016-12-21 Myriad Genetics, Inc. Method for predicting the response and survival from chemotherapy in patients with breast cancer
CN106480201A (zh) 2016-10-26 2017-03-08 北京鑫诺美迪基因检测技术有限公司 乳腺癌转移评估试剂盒

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070134688A1 (en) * 2005-09-09 2007-06-14 The Board Of Regents Of The University Of Texas System Calculated index of genomic expression of estrogen receptor (er) and er-related genes
US20100105564A1 (en) * 2006-09-15 2010-04-29 Mcgill University Stroma Derived Predictor of Breast Cancer
US20110145176A1 (en) * 2008-05-30 2011-06-16 Perou Charles M Gene expression profiles to predict breast cancer outcomes

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329624B2 (en) 2001-12-21 2019-06-25 Biotheranostics, Inc. Grading of breast cancer
US10851427B2 (en) 2010-03-31 2020-12-01 Myriad International Gmbh Method for breast cancer recurrence prediction under endocrine treatment
US11913078B2 (en) 2010-03-31 2024-02-27 Myriad International Gmbh Method for breast cancer recurrence prediction under endocrine treatment
WO2015038682A1 (en) * 2013-09-11 2015-03-19 bio Theranostics, Inc. Predicting breast cancer recurrence
WO2015042570A1 (en) * 2013-09-23 2015-03-26 The University Of Chicago Methods and compositions relating to cancer therapy with dna damaging agents
US11898209B2 (en) 2015-03-25 2024-02-13 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
US11459617B2 (en) * 2016-04-29 2022-10-04 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
CN110050075A (zh) * 2016-10-27 2019-07-23 通用医疗公司 用于确定特定癌症的癌症疗法的功效的血液样品的数字分析
WO2019051266A3 (en) * 2017-09-08 2019-06-20 Myriad Genetics, Inc. Method of using biomarkers and clinical variables for predicting chemotherapy benefit
US11505832B2 (en) 2017-09-08 2022-11-22 Myriad Genetics, Inc. Method of using biomarkers and clinical variables for predicting chemotherapy benefit

Also Published As

Publication number Publication date
US10577661B2 (en) 2020-03-03
US20170067118A1 (en) 2017-03-09
AU2011234573A1 (en) 2012-09-20
EP2553118B1 (en) 2014-10-15
CA2793133A1 (en) 2011-10-06
US10851427B2 (en) 2020-12-01
CA2793133C (en) 2019-08-20
BR122020016370B1 (pt) 2021-05-11
HK1181817A1 (en) 2013-11-15
JP2016189781A (ja) 2016-11-10
AU2011234573B2 (en) 2015-10-01
JP5940517B2 (ja) 2016-06-29
PL2553118T3 (pl) 2015-03-31
CN105821125A (zh) 2016-08-03
EP2845911A1 (en) 2015-03-11
WO2011120984A1 (en) 2011-10-06
KR20130010048A (ko) 2013-01-24
KR101864855B1 (ko) 2018-07-13
HUE030164T2 (en) 2017-05-29
RU2012146343A (ru) 2014-05-10
US20200224281A1 (en) 2020-07-16
ES2587591T3 (es) 2016-10-25
PT2553118E (pt) 2014-12-17
US20210123107A1 (en) 2021-04-29
PL2845911T3 (pl) 2017-01-31
ZA201207229B (en) 2013-06-26
JP2013523105A (ja) 2013-06-17
UA110790C2 (uk) 2016-02-25
ES2525382T3 (es) 2014-12-23
PT2845911T (pt) 2016-08-25
CN102971435A (zh) 2013-03-13
US11913078B2 (en) 2024-02-27
CN102971435B (zh) 2016-05-11
RU2654587C2 (ru) 2018-05-21
BR112012024718A2 (pt) 2017-01-10
EP2553118A1 (en) 2013-02-06
MX2012011167A (es) 2013-02-07
US20240229150A1 (en) 2024-07-11
EP2845911B1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
US10851427B2 (en) Method for breast cancer recurrence prediction under endocrine treatment
US20200255911A1 (en) Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
US20220307090A1 (en) Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer
US20210062275A1 (en) Methods to predict clinical outcome of cancer
AU2015227398A1 (en) Method for using gene expression to determine prognosis of prostate cancer
AU2015268617A1 (en) Method for breast cancer recurrence prediction under endocrine treatment
US20190010558A1 (en) Method for determining the risk of recurrence of an estrogen receptor-positive and her2-negative primary mammary carcinoma under an endocrine therapy
AU2011234573B8 (en) Method for breast cancer recurrence prediction under endocrine treatment

Legal Events

Date Code Title Description
AS Assignment

Owner name: SIVIDON DIAGNOSTICS GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DARTMANN, MAREIKE;VON TOERNE, CHRISTIAN;KRONENWETT, RALF;AND OTHERS;SIGNING DATES FROM 20120926 TO 20121022;REEL/FRAME:029334/0237

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: MYRIAD INTERNATIONAL GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:SIVIDON DIAGNOSTICS GMBH;REEL/FRAME:059845/0718

Effective date: 20180209